Overview: HLA-B22 Typing TestIntroduction: The HLA-B22 Typing Test detects HLA-B22 antigen to assess transplant compatibility or disease risk, aiding organ matching. Following 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, evaluating disease associations, and improving outcomes in molecular pathology for patients undergoing organ transplantation or with HLA-related disease risks, ensuring precise compatibility assessment.
Other Names: HLA-B22 Assay, HLA-B22 Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology advancements. PCR-based HLA-B22 typing improved in the 2000s, enhancing compatibility assessment.
Purpose: Assesses HLA-B22 for transplant compatibility, guides organ matching, and evaluates disease risk in patients.
Test Parameters: 1. HLA-B22 Antigen
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of transplants, autoimmune diseases, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document history of transplants, autoimmune diseases, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility implications, and potential need for transplant planning.
Procedural Considerations: Uses PCR to detect HLA-B22 antigen. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for transplant compatibility.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: Positive HLA-B22 indicates compatibility or disease risk (e.g., autoimmune disorders), guiding transplant or treatment decisions. Negative results may require alternative HLA typing.
Specialist Consultation: Consult a transplant immunologist or hematologist for result interpretation and transplant planning.
Additional Supporting Tests: HLA-A, HLA-DR typing, or antibody screening to assess transplant compatibility.
Test Limitations: Limited to HLA-B22; other HLA loci may need testing. Clinical correlation is needed.
References: ASHI HLA Guidelines, 2023; Human Immunology, Tait BD, 2022.
